摘要
目的探讨外周血淋巴细胞中EB病毒载量与鼻咽癌诊断、分期及预后的价值。方法采用实时荧光定量基因扩增技术,抽取鼻咽癌患者静脉血2mL,用EDTA-Na2抗凝,用淋巴细胞分离液分离血中淋巴细胞,再用DNA提取液提取淋巴细胞中的EBV-DNA为模板进行扩增检测。结果47例鼻咽癌患者中E-BV-DNA阳性率为63.8%(30/47),对照组61例非鼻咽癌患者中EBV-DNA的阳性率为11.5%(7/61),两者差异有显著性(χ2=32.30,P<0.01)。早期(Ⅰ、Ⅱ期)14例与晚期(Ⅲ、Ⅳ期)16例鼻咽癌患者EBV-DNA含量比较差异有显著性(t=4.65,P<0.01),晚期患者淋巴细胞中EBV-DNA含量明显高于早期患者。结论定量检测外周血淋巴细胞中EBV-DNA对鼻咽癌的诊断、分期和预后有极高参考价值,可做为监测病情及判断疗效的一种有效手段。
[Objective] To study the Epstein-Barr virus（EBV） capacity in outward blood lymphocyte and the value of the nasopharyngeal carcinoma （NPC） diagnosis, stages and prognosis. [Methods] Adopt real time fluorogenie quantitative polymerase chain reaction （FQ-PCR） method, collect venous blood 2 mL. In the way of EDTA- Na2 to combat coagulation and depart the lymphocyte in the blood with the lymphocyte fluid and enlarge and gain the examination by the EBV-DNA model in the lymphocyte from DNA collects fluid. [Result] The EBV-DNA＇s positive rates in NPC patients is 63.8% （30/47）, that of the comparison series non-NPC patient is 11.5% （7/61）, there is the significamt difference （X^2=32.30, P 〈0.01）. There is significant difference of EBV-DNA content between early phase （ Ⅰ, Ⅱ stage, 14 cases） and late period （Ⅲ, Ⅳ stage, 16 cases） NPC patient （t=4.65, P 〈0.01）, EBV- DNA＇s content of patient＇s lymphocyte late period is higher than early phase patient. [Conclusion] The value of the NPC diagnoses, stages and prognosis are quantitative examination in the EBV-DNA in the lymphocyte possess exceedingly tall reference value to the NPC diagnoses, stages and prognos, and it is a kind of valid measure to monitor patient＇s condition and decide curative effect.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2006年第22期3412-3414,共3页
China Journal of Modern Medicine
